Yahoo News - Latest News & Headlines
Merck, Samsung Bioepis launch discounted U.S. Remicade alternative
NEW YORK/SEOUL (Reuters) - Merck & Co and South Korea's Samsung Bioepis Co Ltd said on Monday they have begun selling a less expensive alternative version of Johnson & Johnson's rheumatoid arthritis drug Remicade in the United States, a move that should accelerate price declines for the big-selling medicine. The U.S. and Korean drugmakers said they would sell their version, to be called Renflexis, at 35 percent discount to the list price of J&J's top-selling medicine, or about $735 for a 100 milligram dose.
No comments:
Post a Comment